Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

Haruhiko Otsuka,¹ Takeshi Fukumoto,¹ Naomi Kiyota,² Chihiro Takeomori,¹ Haruki Jimbo,¹ Chikako Nishigori¹
¹Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe; ²Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan

Abstract

Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR) and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST). While acneiform eruptions have been observed in patients receiving other BRAF and EGFR inhibitors, the commonly reported adverse reactions to regorafenib are fatigue and palmar-plantar erythrodysesthesia; cases of acneiform eruptions are rarely reported.¹,²

Surgical resection is the primary indication for gastrointestinal stromal tumors (GIST). However, regorafenib has been approved as a third-line treatment for metastatic GIST.¹,³ Herein, we report, to the best of our knowledge, the first case of severe and delayed acneiform eruptions after 24 months of treatment with regorafenib for GIST.

Case Report

A 61-year-old woman was diagnosed with a small intestine tumor by magnetic resonance imaging. After partial resection, the tumor was diagnosed as a high-risk GIST. The patient developed multiple liver metastases, and imatinib (400 mg/day) was administered as a first-line treatment for 23 months, but was discontinued due to tumor progression. Sunitinib (50 mg/day) was administered as a second-line treatment but was discontinued after the patient developed malaise and hand-foot syndrome. After salvage stereotactic radiation therapy targeting a single progressive metastatic lesion, imatinib (200 mg/day) was reintroduced as a third-line treatment before being discontinued due to tumor progression. Regorafenib (160 mg/day) was administered as a fourth-line treatment. One month later, the dose was reduced to 120 mg/day due to side effects, including hand-foot syndrome. Seven months after beginning regorafenib, tumor progression required radiation therapy twice (50 Gy/4 Fr and 45 Gy/15 Fr, respectively).

Twenty-four months after beginning regorafenib, the patient developed monomorphic pink and brown papules and pustules on her back (Figure 1A-C), diagnosed as neutrophilic suppurative folliculitis (Figure 1D,E) by histopathologic analysis of a hematoxylin-eosin stained skin biopsy specimen. Grocott’s methamine silver staining and periodic-acid-Schiff staining were negative (Figure 1F,G), while Gram staining was partially positive (Figure 1H). The patient had no history of acne on her back and reported no other likely causes for the development of acne. Therefore, we diagnosed acneiform eruptions caused by regorafenib, postponed regorafenib treatment for 2 months, and prescribed topical application of clindamycin phosphate hydrate. The acneiform eruptions significantly improved after 1 month and disappeared after 3 months.

Discussion and conclusions

Aceneiform eruptions are a known adverse reaction to BRAF and EGFR inhibitors. However, regorafenib is different from other BRAF and EGFR inhibitors, and the mechanism of acneiform eruptions is not fully understood. Further studies are needed to elucidate the relationship between acneiform eruptions and regorafenib treatment.
2,4,5 BRAF inhibitors are believed to cause acneiform eruptions by paradoxical activation of the mitogen-activated protein kinase pathway via CRAF, resulting in follicular keratinocyte proliferation.7 EGFR inhibitors may cause acneiform eruptions by inhibiting EGFR on undifferentiated keratinocytes in the epidermis and on follicular keratinocytes, promoting apoptosis in keratinocytes and inducing perifollicular inflammation.4 Other studies have found a positive association between the presence of acneiform eruptions and the efficacy of the aforementioned chemotherapy agents4; our case supports this link, as regorafenib consistently exerted a strong antitumor effect in our patient.

Ultimately, we found that although regorafenib-associated skin toxicities usually appear within 1 month of treatment,8 the patients potentially can present with delayed-onset acneiform eruptions even 24 months later. Treatment with antibiotic ointment and postponed regorafenib administration improved these eruptions in our patient.

References

1. Chamberlain F, Farag S, Williams-Sharkey C, et al. Toxicity management of regorafenib in patients with gastrointestinal stromal tumour (GIST) in a tertiary cancer centre. Clin Sarcoma Res 2020;10:1.

2. Liu YC, Tsai JJ, Weng YS et al. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother 2020;128:110319.

3. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.

4. Brodell LA, Hepper D, Lind A et al. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol 2013;40:865-70.

5. Ansai O, Fujikawa H, Shimomura Y et al. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib. J Dermatol 2017;44:e15-e6.